Status:
COMPLETED
In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Women with advanced maternal age and morbid obesity, have a higher incidence of labor induction/ augmentation and cesarean section (CS), and are at a greater risk for postpartum hemorrhage (PPH). Oxyt...
Detailed Description
In view of the growing concern over the rising incidence of later maternal age and morbid obesity in the obstetric population, scientific evidence on pregnancy outcomes in these patients is timely and...
Eligibility Criteria
Inclusion
- patients who give written informed consent
- patients requiring elective primary or 1st repeat Cesarean section
- patients with gestational age 37-41 weeks
- non-labouring patients, not exposed to exogenous oxytocin
- Cesarean section under spinal anesthetic
- patients \<30 years of age with a normal pre-pregnancy BMI (20 and 24.9 kg/m2)
- patients ≥40 years of age with a normal pre-pregnancy BMI
- patients with a BMI≥40 kg/m2 and age \<30 years
Exclusion
- patients who refuse to give written informed consent
- patients who require general anesthesia
- patients who have had more than one previous uterine surgery/CS
- patients with placental abnormalities (abruption, accreta, percreta)
- patients with bleeding disorders
- presence of any other risk factors for PPH
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 13 2017
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01865669
Start Date
May 1 2013
End Date
June 13 2017
Last Update
February 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G1X5